FAMAR Group announces acquisition of sterile manufacturing site in Homburg, Germany

"The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce," said Konstantinos Rengis, CEO of FAMAR Group. "This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together". " The...

Germany, 14/05/2025 (informazione.news - comunicati stampa - salute e benessere)

" ," said Konstantinos Rengis , CEO of FAMAR Group. " ".

As part of the transaction, approximately 100 employees will transfer to FAMAR, ensuring continuity and knowledge retention. The site will be developed into a multi-customer CDMO platform, fully aligned with FAMAR's ambition to lead in complex and high-value pharmaceutical manufacturing.

Dr. Friedrich Sernetz, CEO of MiP Pharma, highlighted: " ".

Matthew Strassberg , Partner and Head of Healthcare Sector Practice at MidEuropa commented: " ".

FAMAR is a leading European provider of pharmaceutical and cosmetic manufacturing and development services. With a legacy of 75 years, FAMAR delivers high-quality dosage forms, including sterile liquids, solids, and semi-solids, creating value for its clients. Operating in Spain , Italy , and Greece , employing over 1.850 people across a network of six production facilities and two R&D centers, FAMAR supplies a wide range of more than 1.700 different products for over 80 international markets.

MiP Pharma Group markets prescription generics, primarily antibiotics, over-the-counter medicines and medical devices.. The sales focus is on the hospital business and addressing selected specialist groups. With over 200 employees and around 400 marketing authorisations, MiP Pharma generated sales of around 50 million euros in the last financial year. Since November 2020 , MiP Pharma has been a portfolio company of the Berlin -based financial investor capiton AG.

View original content:https://www.prnewswire.co.uk/news-releases/famar-group-announces-acquisition-of-sterile-manufacturing-site-in-homburg-germany-302455286.html